Seres Therapeutics Inc (NAS:MCRB)
$ 0.9577 -0.09 (-8.57%) Market Cap: 145.94 Mil Enterprise Value: 298.35 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100
Back to the Transcripts List

Q2 2024 Seres Therapeutics Inc Earnings Call Transcript

Aug 13, 2024 / 12:30PM GMT
Release Date Price: $0.828 (-6.97%)

Key Points

Positve
  • Seres Therapeutics Inc (MCRB) announced the sale of VOWST assets to Nestle Health Science, providing a substantial immediate and future financial consideration.
  • The VOWST asset sale will provide Seres Therapeutics Inc (MCRB) with $155 million in cash, strengthening their balance sheet and enabling debt retirement.
  • Seres Therapeutics Inc (MCRB) has developed VOWST, the first FDA-approved oral live microbiome therapy, transforming the lives of patients with recurrent C. difficile infections.
  • The company is advancing its pipeline with promising programs like SER-155 and SER-147, targeting significant unmet medical needs in vulnerable patient populations.
  • Seres Therapeutics Inc (MCRB) reported a 43% growth in VOWST net sales for the second quarter, reflecting strong market potential and execution.
Negative
  • Seres Therapeutics Inc (MCRB) reported a net loss of $32.9 million for the second quarter of 2024, compared to net income of $46.6 million for the same period in 2023.
  • The company will not recognize VOWST net sales in its financial statements, sharing equally the product's commercial profits and losses with Nestle.
  • Research and development expenses for the second quarter were $17.9 million, indicating ongoing high costs despite a decrease from the previous year.
  • General and administrative expenses for the second quarter were $16.1 million, reflecting significant operational costs.
  • The company's future cash runway is dependent on the successful completion of the VOWST asset sale and subsequent capital infusion.
Operator

Good day, and thank you for standing by. At this time, I would like to welcome everyone to Seres Therapeutics second quarter 2024 earnings conference call.

(Operator Instructions)

I would now like to turn the conference over to Dr. Carlo Tanzi, Investor Relations. Please go ahead.

Carlo Tanzi
Seres Therapeutics Inc - Investor Relations

Thank you, and good morning. Our press release with the company's second quarter 2024 financial results and a business update became available at 7:00AM Eastern Time this morning and can be found on the Investors & News section of the company's website. The company has also posted an updated corporate presentation to the website.

I'd like to remind you that we'll be making forward-looking statements, including related to the financial terms, timing and completion of the sale of VOWST assets to Nestle Health Science. The receipt of future payments and the use of proceeds of the transaction, the timing and results of clinical studies and data readouts, development plans and commercial opportunities

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.